BLUE bluebird bio Inc.

145.8
-0.84  -1%
Previous Close 146.64
Open 146.45
Price To Book 4.25
Market Cap 8011881607
Shares 54,951,177
Volume 326,754
Short Ratio
Av. Daily Volume 552,663

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2019.
LentiGlobin - HGB-210
Sickle Cell Disease (SCD)
Phase 3 presentation of data by mid-2019 and by end of 2019.
LentiGlobin - HGB-212 Northstar-3
TDT and the β0/β0genotype
Phase 2 data due by the end of 2019.
bb2121 - KarMMa
Relapsed/refractory multiple myeloma
Phase 3 presentation of data by mid-2019 and by end of 2019.
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
Phase 2/3 updated data released September 5, 2018.
Lenti-D - Starbeam
Childhood cerebral adrenoleukodystrophy (CCALD)
Updated data presented at ASH December 5, 2016.
LentiGlobin - HGB-204
β-Thalassemia
Phase 1/2 presentation of data by mid-2019 and by end of 2019.
LentiGlobin - HGB-206
Sickle disease
Phase 1 data due by the end of 2019.
bb21217
Multiple Myeloma

Latest News

  1. Massachusetts concern details plan to hire new workers in Durham
  2. Why Is Bluebird (BLUE) Up 15.3% Since Last Earnings Report?
  3. bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina
  4. See what the IHS Markit Score report has to say about bluebird bio Inc.
  5. Celgene (CELG) Submits Application for MS Drug in Europe
  6. Here's Why bluebird bio Gained 16.3% in February
  7. bluebird bio to Present at Investor Conferences in March
  8. What Are Analysts Saying About bluebird bio, Inc.’s (NASDAQ:BLUE) Earnings Outlook?
  9. With a Stocked War Chest, bluebird bio Presses On
  10. Biotech ETFs Jump on Roche-Spark Deal
  11. Better Buy: bluebird bio vs. Gilead Sciences
  12. bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y
  13. Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates
  14. Bluebird: 4Q Earnings Snapshot
  15. bluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress
  16. Report: Exploring Fundamental Drivers Behind Tyson Foods, ElectraMeccanica Vehicles, Cousins Properties, Spirit Aerosystems, bluebird bio, and Yext — New Horizons, Emerging Trends, and Upcoming Developments
  17. Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
  18. AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma
  19. bluebird bio Appoints Chip Baird as Chief Financial Officer